DDInter1286 DDInter1763
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Niacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Niacin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Niacin {u} (Compound) upregulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Niacin {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Niacin {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Niacin {u} (Compound) causes {v} (Side Effect) Face oedema
Face oedema {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Niacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Niacin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Niacin {u} (Compound) upregulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Niacin {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) regulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Niacin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Temsirolimus (Compound)
Niacin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Temsirolimus (Compound)
Niacin (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is downregulated by Temsirolimus (Compound)
Niacin (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Temsirolimus (Compound)
Niacin (Compound) causes Face oedema (Side Effect) and Face oedema (Side Effect) is caused by Temsirolimus (Compound)
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Niacin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Niacin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Niacin (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) regulates NUCB2 (Gene) and NUCB2 (Gene) is upregulated by Temsirolimus (Compound)